Quarterly ResultAug 12, 2026, 04:38 PM
Lucid Diagnostics Q2 Revenue $1.47M; Going Concern Doubt
AI Summary
Lucid Diagnostics Inc. reported its second-quarter and six-month financial results for 2026, showing a significant increase in revenue but continued net losses. The company's management raised substantial doubt about its ability to continue as a going concern, citing ongoing losses and negative cash flows from operations. Revenue for the six months ended June 30, 2026, grew to $2.73 million, a 37.1% increase year-over-year, while the net loss attributable to common stockholders was $38.34 million. The company ended the period with $33.40 million in cash.
Key Highlights
- Company raised substantial doubt about its ability to continue as a going concern.
- Revenue for six months ended June 30, 2026, increased 37.1% to $2.73 million.
- Net loss attributable to common stockholders for six months ended June 30, 2026, was $38.34 million.
- Net loss per share for six months ended June 30, 2026, was $0.24, an improvement from $0.52.
- Cash balance as of June 30, 2026, was $33.40 million, down from $34.71 million.
- Net cash used in operating activities for six months ended June 30, 2026, was $23.40 million.
- Working capital as of June 30, 2026, was $9.1 million, including $23.5 million in convertible notes.
Price Impact
More from LUCD